During April 2025, the registered number of shares and votes in Immunovia AB (publ) (“Immunovia”) has increased due exercise of warrants of series TO 3. As of 30 April 2025, the registered number of shares and votes in Immunovia amounts to 306,083,080.
For further information, please contact
Jeff Borcherding, CEO
jeff.borcherding@immunovia.com
This information is such information that Immunovia AB (publ) is obliged to make public pursuant to the Financial Instruments Trading Act. The information was submitted for publication, through the agency of the contact persons set out above, on 30 April 2025 at 09.45 CEST.
Immunovia in brief
Immunovia AB is a diagnostic company whose mission is to increase survival rates for patients with pancreatic cancer through early detection. Immunovia is focused on the development and commercialization of simple blood-based testing to detect proteins and antibodies that indicate a high-risk individual has developed pancreatic cancer. Immunovia collaborates and engages with healthcare providers, leading experts and patient advocacy groups to make its test available to individuals at increased risk for pancreatic cancer.
USA is the world’s largest market for detection of pancreatic cancer. The Company estimates that in the USA, 1.8 million individuals are at high-risk for pancreatic cancer and could benefit from annual surveillance testing.
Immunovia’s shares (IMMNOV) are listed on Nasdaq Stockholm.
For more information, please visit www.immunovia.com.
This information is information that Immunovia is obliged to make public pursuant to the Financial Instruments Trading Act. The information was submitted for publication at 2025-04-30 09:45 CEST.